Territorial Availability: Available through Bertin Technologies only in France
- Synonyms
- 1,2-benzisoxazole-3-methanesulfonamide
- Correlated keywords
- 892699-17-1 Zonegran AD-810 AD810 CI912 Exceglan Excegram Excegran PD110843
- Product Overview:
Zonisamide is a broad-spectrum sulfonamide antiepileptic agent.{41543} It selectively blocks the repeated firing of sodium channels (IC50 = 2 ?g/ml) at low concentrations in mouse embryo spinal cord neurons, and it blocks spontaneous channel firing at concentrations above 10 ?g/ml.{41545} In rat cerebral cortex neurons, zonisamide (1-1000 ?M) dose-dependently blocks T-type calcium channels with a maximum reduction of 60% of the calcium current.{41546} Zonisamide inhibits recombinant H. pylori carbonic anhydrase (CA) and human CA isoforms I, II, and V with Ki values of 218, 56, 35, and 21 nM, respectively.{33180,41544} Zonisamide has anticonvulsant activity in rats, rabbits, dogs, and mice with a potency similar to phenobarbital (Item No. 9001494) and carbamazepine in maximal electroshock seizure (MES) models.{41543} In mice, it has anticonvulsant activity against MES and pentylenetetrazole-induced maximal and minimal seizures with median effective doses of 19.6, 9.3, and >500 mg/kg, respectively. Zonisamide (10-100 mg/kg, p.o.) dose-dependently prevents reduction of dopamine (Item No. 21992), homovanillic acid (HVA), and dihydroxyphenyl acetic acid (DOPAC) levels and the elevation of the dopamine turnover rate induced by MPTP in mouse striatum. Formulations containing zonisamide have been used in the treatment of partial seizures in adults with epilepsy.
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.